<DOC>
	<DOCNO>NCT00834106</DOCNO>
	<brief_summary>A study test safety effectiveness Quadrivalent HPV ( type 6 , 11 , 16 , 18 ) L1 VLP vaccine combine incidence HPV 6/11/16/18-related persistent infection vaccine type-specific genital disease among Chinese female age 20 45 .</brief_summary>
	<brief_title>Prevention HPV 20 45 Year Old Chinese Women ( V501-041 )</brief_title>
	<detailed_description>The Base Study V501-041 plan duration 30 month . The study extend evaluate efficacy Quadrivalent HPV ( Type 6 , 11 , 16 , 18 ) L1 VLP ( qHPV ) vaccine Cervical Intraepithelial Neoplasia Grade 2 ( CIN 2 ) , CIN 3 , Adenocarcinoma In Situ ( AIS ) , and/or cervical cancer . The total duration study extension expect approximately 48 month , requisite number primary efficacy endpoint case ( HPV 16/18-related CIN 2 worse ) accrue total study period ( base study extension ) .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy woman age 20 45 Have use effective contraception 2 week prior start study Does temperature within 24 hour first injection Prior history genital warts More 4 lifetime sexual partner Have undergone hysterectomy Have active cervical disease history cervical disease</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HPV 6/11/16/18 Infection</keyword>
</DOC>